HC Wainwright Predicts Higher Earnings for Nuvectis Pharma

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Nuvectis Pharma to ($0.26), previously ($0.28), while maintaining a "Buy" rating and a target price of $10.00.
• Nuvectis reported a Q2 EPS of ($0.30), missing the consensus estimate by ($0.05), indicating challenges in meeting performance expectations.
• Insider Marlio Charles Mosseri recently acquired an additional 5,603 shares, increasing their ownership stake to approximately 30.52% of the company.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Stock analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for Nuvectis Pharma in a research report issued on Tuesday, August 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.26) per share for the quarter, up from their previous forecast of ($0.28). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma's Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($1.52) EPS, FY2027 earnings at ($1.73) EPS and FY2028 earnings at ($2.03) EPS.

Separately, Wall Street Zen cut Nuvectis Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, June 29th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Nuvectis Pharma presently has a consensus rating of "Buy" and a consensus price target of $15.33.

Nuvectis Pharma Trading Down 4.4%

NASDAQ NVCT traded down $0.2850 on Thursday, hitting $6.1650. 29,083 shares of the company's stock were exchanged, compared to its average volume of 145,206. The stock has a 50-day moving average of $7.60 and a 200-day moving average of $8.26. Nuvectis Pharma has a 52 week low of $4.44 and a 52 week high of $11.80. The stock has a market cap of $156.96 million, a price-to-earnings ratio of -5.28 and a beta of -0.26.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.05).

Insider Activity at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri purchased 28,043 shares of the company's stock in a transaction dated Wednesday, June 18th. The stock was bought at an average cost of $8.05 per share, for a total transaction of $225,746.15. Following the purchase, the insider owned 2,976,203 shares of the company's stock, valued at approximately $23,958,434.15. The trade was a 0.95% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders acquired 39,045 shares of company stock valued at $314,300. 30.52% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey bought a new position in Nuvectis Pharma during the 2nd quarter worth $28,000. JPMorgan Chase & Co. raised its position in Nuvectis Pharma by 3,398.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company's stock worth $47,000 after purchasing an additional 6,084 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Nuvectis Pharma during the 4th quarter worth $34,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Nuvectis Pharma during the 2nd quarter worth $53,000. Finally, Bank of America Corp DE raised its position in Nuvectis Pharma by 417.2% during the 2nd quarter. Bank of America Corp DE now owns 8,565 shares of the company's stock worth $64,000 after purchasing an additional 6,909 shares during the last quarter. 96.77% of the stock is owned by institutional investors.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.